Table 2 Patient characteristics and pMMA and uMMA values of a subset of individuals from the MARLINA trial. Number of samples in each group and subgroup.
From: Linagliptin treatment is associated with altered cobalamin (VitB12) homeostasis in mice and humans
Groups | Plasma | Urine |
|---|---|---|
Total | 301 | 245 |
White | 60 | 60 |
Asian | 183 | 183 |
Other/Unknown | 58 | 2 |
Linagliptin | 151 | 120 |
Placebo | 150 | 125 |